Oncology: International Journal of Cancer Research and Treatment
Fecha de publicación: October 2019
Autores: Faehling M., Kopp M., Schwenk B., Fallscheer S., Kramberg S., Eckert R.
Background: Immuno-oncological (IO) therapies such as PD-1 and PD-L1 antibodies have been introduced in the treatment of advanced non-small cell lung cancer (NSCLC) since 2015 based on randomized trials showing unprecedented advantages in overall survival (OS) with hazard ratios (HRs) between 0.5 and 0.7. The impact of these treatments on OS in routine clinical practice and the role of tumor mass have not been studied.Leer más